Literature DB >> 27599775

Influence of the availability of iron during hypoxia on the genes associated with apoptotic activity and local iron metabolism in rat H9C2 cardiomyocytes and L6G8C5 skeletal myocytes.

Magdalena Dziegala1, Monika Kasztura2, Kamil Kobak3, Jacek Bania4, Waldemar Banasiak5, Piotr Ponikowski2, Ewa A Jankowska3.   

Abstract

The differential availability of iron during hypoxia is presumed to affect the functioning of cardiac and skeletal myocytes. Rat H9C2 cardiomyocytes and L6G8C5 myocytes were cultured for 48 h in normoxic or hypoxic conditions at the optimal, reduced or increased iron concentration. The mRNA expression levels of markers of apoptosis [B‑cell lymphoma‑2 (Bcl2; inhibition) and Bcl‑2‑activated X protein (Bax; induction)], atrophy (Atrogin), glycolysis (pyruvate kinase 2; PKM2) and iron metabolism [transferrin receptor 1 (TfR1; iron importer), ferroportin 1 (FPN1; iron exporter), ferritin heavy chain (FTH; iron storage protein) and hepcidin (HAMP; iron regulator)] were determined using reverse transcription‑quantitative polymerase chain reaction, and cell viability was measured using an tetrazolium reduction assay. Cardiomyocytes and myocytes, when exposed to hypoxia, demonstrated an increased Bax/Bcl‑2 gene expression ratio (P<0.05). Additional deferoxamine (DFO) treatment resulted in further increases in Bax/Bcl‑2 in each cell type (P<0.001 each) and this was associated with the 15% loss in viability. The analogous alterations were observed in both cell types upon ammonium ferric citrate (AFC) treatment during hypoxia; however, the increased Bax/Bcl‑2 ratio and associated viability loss was lower compared with that in case of DFO treatment (P<0.05 each). Under hypoxic conditions, myocytes demonstrated an increased expression of PKM2 (P<0.01). Additional DFO treatment caused an increase in the mRNA expression levels of PKM2 and Atrogin‑1 (P<0.001 and P<0.05, respectively), whereas AFC treatment caused an increased mRNA expression of PKM2 (P<0.01) and accompanied decreased mRNA expression of Atrogin‑1 (P<0.05). The expression augmentation of PKM2 during hypoxia was greater upon low iron compared with that of ferric salt treatment (P<0.01). Both cell types upon DFO during hypoxia demonstrated the increased expression of TfR1 and HAMP (all P<0.05), which was associated with the increased Bax/Bcl‑2 ratio (all R>0.6 and P<0.05). In conclusion, during hypoxia iron deficiency impairs the viability of cardiomyocytes and myocytes more severely compared with iron excess. In myocytes, during hypoxia iron may act in a protective manner, since the level of atrophy is decreased in the iron‑salt‑treated cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27599775     DOI: 10.3892/mmr.2016.5705

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

Review 1.  In-depth review: is hepcidin a marker for the heart and the kidney?

Authors:  Rengin Elsurer Afsar; Mehmet Kanbay; Avsin Ibis; Baris Afsar
Journal:  Mol Cell Biochem       Date:  2021-05-04       Impact factor: 3.396

2.  Impact of different methods of induction of cellular hypoxia: focus on protein homeostasis signaling pathways and morphology of C2C12 skeletal muscle cells differentiated into myotubes.

Authors:  Samir Bensaid; Claudine Fabre; Julie Fourneau; Caroline Cieniewski-Bernard
Journal:  J Physiol Biochem       Date:  2019-07-02       Impact factor: 4.158

3.  Potential role for pyruvate kinase M2 in the regulation of murine cardiac glycolytic flux during in vivo chronic hypoxia.

Authors:  Michal K Handzlik; David J Tooth; Dumitru Constantin-Teodosiu; Paul L Greenhaff; Mark A Cole
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

4.  Iron limitation promotes the atrophy of skeletal myocytes, whereas iron supplementation prevents this process in the hypoxic conditions.

Authors:  Kamil Kobak; Monika Kasztura; Magdalena Dziegala; Jacek Bania; Violetta Kapuśniak; Waldemar Banasiak; Piotr Ponikowski; Ewa A Jankowska
Journal:  Int J Mol Med       Date:  2018-02-12       Impact factor: 4.101

5.  Intrinsic Iron Release Is Associated with Lower Mortality in Patients with Stable Coronary Artery Disease-First Report on the Prospective Relevance of Intrinsic Iron Release.

Authors:  Julia Ruhe; Christoph Waldeyer; Francisco Ojeda; Alev Altay; Renate B Schnabel; Sarina Schäfer; Karl J Lackner; Stefan Blankenberg; Tanja Zeller; Mahir Karakas
Journal:  Biomolecules       Date:  2018-08-09

6.  Iron Metabolism Contributes to Prognosis in Coronary Artery Disease: Prognostic Value of the Soluble Transferrin Receptor Within the AtheroGene Study.

Authors:  Henri Weidmann; Johannes H Bannasch; Christoph Waldeyer; Apurva Shrivastava; Sebastian Appelbaum; Francisco Miguel Ojeda-Echevarria; Renate Schnabel; Karl J Lackner; Stefan Blankenberg; Tanja Zeller; Mahir Karakas
Journal:  J Am Heart Assoc       Date:  2020-04-23       Impact factor: 5.501

Review 7.  Iron Deficiency in Heart Failure: Mechanisms and Pathophysiology.

Authors:  Ridha I S Alnuwaysir; Martijn F Hoes; Dirk J van Veldhuisen; Peter van der Meer; Niels Grote Beverborg
Journal:  J Clin Med       Date:  2021-12-27       Impact factor: 4.964

8.  Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome.

Authors:  Tanja Zeller; Christoph Waldeyer; Francisco Ojeda; Renate B Schnabel; Sarina Schäfer; Alev Altay; Karl J Lackner; Stefan D Anker; Dirk Westermann; Stefan Blankenberg; Mahir Karakas
Journal:  Biomolecules       Date:  2018-07-20

Review 9.  Structural and functional abnormalities in iron-depleted heart.

Authors:  Kamil A Kobak; Malwina Radwańska; Magdalena Dzięgała; Monika Kasztura; Krystian Josiak; Waldemar Banasiak; Piotr Ponikowski; Ewa A Jankowska
Journal:  Heart Fail Rev       Date:  2019-03       Impact factor: 4.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.